Evidence map›Paper›PMID 37803920›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2024

Sex Influences the Safety and Therapeutic Efficacy of Cardiac Nanomedicine Technologies.

Zijin Lin, Zahra Jiwani, Vahid Serpooshan, Haniyeh Aghaverdi, Phillip C Yang, Aitor Aguirre, Joseph C Wu, Morteza Mahmoudi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zijin LinDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.
Zahra JiwaniDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.
Vahid SerpooshanDepartment of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Haniyeh AghaverdiDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.
Phillip C YangDepartment of Medicine, Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, 94309, USA.
Aitor AguirreRegenerative Biology and Cell Reprogramming Laboratory, Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI, 48823, USA.
Joseph C WuDepartment of Medicine, Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, 94309, USA.
Morteza MahmoudiDepartment of Radiology and Precision Health Program, Michigan State University, East Lansing, MI, 48824, USA.

Funding

Oxylipin Signaling in Congenital Heart DiseaseR01HL151505 · NHLBI · MICHIGAN STATE UNIVERSITY · PI AGUIRRE, AITOR · 2021 to 2025
$2.2M
A Nanostructured Skin Patch to Heal Chronic WoundsR01DK131417 · NIDDK · MICHIGAN STATE UNIVERSITY · PI Morteza Mahmoudi · 2022 to 2026
$2.0M
NHLBI NIH HHS R01 HL151505NIDDK NIH HHS R01 DK131417
6 · The paper itself

Abstract

Nanomedicine technologies are being developed for the prevention, diagnosis, and treatment of cardiovascular disease (CVD), which is the leading cause of death worldwide. Before delving into the nuances of cardiac nanomedicine, it is essential to comprehend the fundamental sex-specific differences in cardiovascular health. Traditionally, CVDs have been more prevalent in males, but it is increasingly evident that females also face significant risks, albeit with distinct characteristics. Females tend to develop CVDs at a later age, exhibit different clinical symptoms, and often experience worse outcomes compared to males. These differences indicate the need for sex-specific approaches in cardiac nanomedicine. This Perspective discusses the importance of considering sex in the safety and therapeutic efficacy of nanomedicine approaches for the prevention, diagnosis, and treatment of CVD.

Indexed as

Cardiovascular DiseasesNanomedicineAnimalsFemaleHumansMaleSex Factorscardiac nanomedicinecell sexcell therapysex‐specific therapy

Identifiers

PMID37803920
PMCPMC10997742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.